(Q35904825)

11 August 2017

1 reference

title

Role of fibric acid derivatives in the management of risk factors for coronary heart disease (English)

1 reference

11 August 2017

main subject

coronary artery disease

1 reference

1

Jean-Pierre Després

1 reference

11 August 2017

Isabelle Lemieux

2

1 reference

11 August 2017

Sander J Robins

series ordinal

3

1 reference

11 August 2017

publication date

1 January 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

64

1 reference

11 August 2017

issue

19

1 reference

11 August 2017

page(s)

2177-2198

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200464190-00003

11 August 2017

exact match

0 references

cites work

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Mechanistic studies on metabolic interactions between gemfibrozil and statins

1 reference

12 December 2020

High density lipoprotein subfractions in non-insulin-dependent diabetes mellitus and coronary artery disease.

1 reference

12 December 2020

Abdominal obesity as important component of insulin-resistance syndrome

1 reference

12 December 2020

Serum triglycerides as an independent risk factor for death from coronary heart disease in middle-aged Norwegian men.

1 reference

12 December 2020

Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men.

1 reference

12 December 2020

Fibrinogen, obesity and insulin resistance

1 reference

12 December 2020

Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor

1 reference

12 December 2020

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

12 December 2020

Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia

1 reference

12 December 2020

Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.

1 reference

12 December 2020

George Lyman Duff Memorial Lecture. Atherogenesis in diabetes

1 reference

12 December 2020

Health consequences of visceral obesity

1 reference

12 December 2020

Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction

1 reference

12 December 2020

Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

Serum cholesterol and triglycerides in patients suffering from ischemic heart disease and in healthy subjects

1 reference

12 December 2020

Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study

1 reference

12 December 2020

Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates

1 reference

12 December 2020

Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Results from the Québec cardiovascular study

1 reference

12 December 2020

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study

1 reference

12 December 2020

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

1 reference

12 December 2020

Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia

1 reference

12 December 2020

Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study

1 reference

12 December 2020

PAI-1, obesity, insulin resistance and risk of cardiovascular events

1 reference

12 December 2020

High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study

1 reference

12 December 2020

Effect of gemfibrozil on lipids, apoproteins, and postheparin lipolytic activities in normolipidemic subjects

1 reference

12 December 2020

Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group

1 reference

12 December 2020

Clustering of cardiovascular risk factors in type 2 diabetes mellitus: prognostic significance and tracking

1 reference

12 December 2020

Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension

1 reference

12 December 2020

Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells

1 reference

12 December 2020

Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia

1 reference

12 December 2020

Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).

1 reference

12 December 2020

Epidemiology of coronary heart disease: the Framingham study.

1 reference

12 December 2020

Cholesterol and coronary heart disease: predicting risks by levels and ratios

1 reference

12 December 2020

Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study

1 reference

12 December 2020

Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region

1 reference

12 December 2020

Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women

1 reference

12 December 2020

The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men.

1 reference

12 December 2020

Bezafibrate in men with lower extremity arterial disease: randomised controlled trial

1 reference

12 December 2020

Prediction of Coronary Heart Disease Using Risk Factor Categories

1 reference

12 December 2020

Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus

1 reference

12 December 2020

Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study

1 reference

12 December 2020

Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women.

1 reference

12 December 2020

The associations of high-density lipoprotein subclasses with insulin and glucose levels, physical activity, resting heart rate, and regional adiposity in men with coronary artery disease: the Stanford Coronary Risk Intervention Project baseline surv

1 reference

12 December 2020

Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol

1 reference

12 December 2020

A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators

1 reference

12 December 2020

Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study

1 reference

12 December 2020

Low density lipoprotein particle size and coronary artery disease

1 reference

12 December 2020

Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study

1 reference

12 December 2020

Effects of fenofibrate on angiographically examined coronary atherosclerosis and left ventricular function in hypercholesterolemic patients

1 reference

12 December 2020

Mechanism of action of fibrates on lipid and lipoprotein metabolism

1 reference

12 December 2020

Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT).

1 reference

12 December 2020

Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group

1 reference

12 December 2020

Blood pressure and high blood pressure. Aspects of risk

1 reference

12 December 2020

Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study

1 reference

12 December 2020

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

12 December 2020

Effect of a combination of gemfibrozil and niacin on lipid levels

1 reference

12 December 2020

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

1 reference

12 December 2020

Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study

1 reference

12 December 2020

Gemfibrozil Reduces Plasma C-Reactive Protein Levels in Abdominally Obese Men With the Atherogenic Dyslipidemia of the Metabolic Syndrome

1 reference

12 December 2020

Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians

1 reference

12 December 2020

Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?

1 reference

12 December 2020

Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease

1 reference

12 December 2020

Adipose tissue distribution and plasma lipoprotein levels in obese women. Importance of intra-abdominal fat

1 reference

12 December 2020

Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies

1 reference

12 December 2020

Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Tr

1 reference

12 December 2020

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

12 December 2020

Diabetes and the cardiologists: a call to action

1 reference

12 December 2020

Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials

1 reference

12 December 2020

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

12 December 2020

HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study

1 reference

12 December 2020

Effect of gemfibrozil on apolipoprotein B secretion and diacylglycerol acyltransferase activity in human hepatoblastoma (HepG2) cells

1 reference

12 December 2020

Mechanism of action of gemfibrozil on lipoprotein metabolism

1 reference

12 December 2020

A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration

1 reference

12 December 2020

Association between baseline risk factors, cigarette smoking, and CHD mortality after 10.5 years. MRFIT Research Group

1 reference

12 December 2020

A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction

1 reference

12 December 2020

Inflammation and atherosclerosis

1 reference

12 December 2020

Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor

1 reference

12 December 2020

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

1 reference

12 December 2020

Usefulness of visceral obesity (waist/hip ratio) in predicting vascular endothelial function in healthy overweight adults

1 reference

12 December 2020

Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol.

1 reference

12 December 2020

Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid

1 reference

12 December 2020

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

1 reference

12 December 2020

Clofibrate and niacin in coronary heart disease

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

12 December 2020

Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages

1 reference

12 December 2020

Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity

1 reference

12 December 2020

Plasma triglyceride and coronary heart disease

1 reference

12 December 2020

Induction of plasminogen activator inhibitor-1 in endothelial cells by basic fibroblast growth factor and its modulation by fibric acid

1 reference

12 December 2020

Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance

1 reference

12 December 2020

Treatment of obesity: need to focus on high risk abdominally obese patients

1 reference

12 December 2020

Triglyceride as a risk factor for coronary artery disease.

1 reference

12 December 2020

The role of fibric acids in atherosclerosis

1 reference

12 December 2020

Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Québec Cardiovascular Study)

1 reference

12 December 2020

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

1 reference

12 December 2020

HDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study.

1 reference

12 December 2020

Opposite in vitro and in vivo regulation of hepatic apolipoprotein A-I gene expression by retinoic acid. Absence of effects on apolipoprotein A-II gene expression

1 reference

12 December 2020

Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study

1 reference

12 December 2020

Anthropometric, computed tomography and fat cell data in an obese population: relationship with insulin, leptin, tumor necrosis factor-alpha, sex hormone-binding globulin and sex hormones.

1 reference

12 December 2020

Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway

1 reference

12 December 2020

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

1 reference

12 December 2020

Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group

1 reference

12 December 2020

Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study.

1 reference

12 December 2020

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

1 reference

12 December 2020

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

12 December 2020

Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in rat aortic smooth muscle cells

1 reference

12 December 2020

Increase in hepatic expression of SREBP-2 by gemfibrozil administration to rats

1 reference

12 December 2020

Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients

1 reference

12 December 2020

Lipoprotein metabolism in diabetes mellitus

1 reference

12 December 2020

C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?

1 reference

12 December 2020

Plasma triglyceride as a risk factor for coronary heart disease. The epidemiologic evidence and beyond

1 reference

12 December 2020

The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study

1 reference

12 December 2020

Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance

1 reference

12 December 2020

Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Expression of peroxisome proliferator-activated receptor subtypes in human atherosclerosis

1 reference

12 December 2020

Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease.

1 reference

12 December 2020

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators

1 reference

12 December 2020

Combination drug therapy for familial combined hyperlipidemia

1 reference

12 December 2020

Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

1 reference

12 December 2020

Visceral Obesity in Men: Associations With Glucose Tolerance, Plasma Insulin, and Lipoprotein Levels

1 reference

12 December 2020

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment

1 reference

12 December 2020

PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells

1 reference

12 December 2020

Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

1 reference

12 December 2020

Statin-associated myopathy

1 reference

12 December 2020

Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study

1 reference

12 December 2020

WHO clofibrate/cholesterol trial: clarifications

1 reference

12 December 2020

Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease

1 reference

12 December 2020

Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

1 reference

12 December 2020

Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells

1 reference

12 December 2020

Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein

1 reference

12 December 2020

Cholesterol and coronary heart disease: predicting risks in men by changes in levels and ratios

1 reference

12 December 2020

Hypertriglyceridemia, insulin resistance, and the metabolic syndrome

1 reference

12 December 2020

Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study

1 reference

12 December 2020

Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients

1 reference

12 December 2020

10.2165/00003495-200464190-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

11 August 2017

1017592605

0 references

1 reference